Allarity Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Allarity Therapeutics is Thomas Jensen, benoemd in Jan2004, heeft een ambtstermijn van 20.83 jaar. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde $ 3.97. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.2 jaar en 2.1 jaar.

Belangrijke informatie

Thomas Jensen

Algemeen directeur

US$24.7k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	20.8yrs
Eigendom CEO	0.00007%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

CEO

Thomas Jensen (46 yo)

20.8yrs

Tenure

US$24,720

Compensatie

Mr. Thomas H. Jensen is Co-Founder of Allarity Therapeutics, Inc. and serves as its Director since July 7, 2022. He is Chief Executive Officer since December 08, 2023 at Allarity Therapeutics, Inc. and ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Jensen	Founder	20.8yrs	US$24.72k	0.000070% $ 4.0
Steen Knudsen	Founder & Chief Scientific Officer	20.8yrs	US$266.22k	0.000070% $ 4.0
Jeremy Graff	President & Chief Development Officer	less than a year	geen gegevens	geen gegevens
Peter Jensen	Co-Founder	no data	US$128.02k	geen gegevens
Alexander Epshinsky	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Jose Iglesias	Consultant Chief Medical Officer	less than a year	geen gegevens	geen gegevens

0.2yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALLR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Jensen	Founder	2.3yrs	US$24.72k	0.000070% $ 4.0
Daniel Von Hoff	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gerald McLaughlin	Independent Chairman of the Board	2.1yrs	US$107.38k	0.000070% $ 4.0
Joyce O'Shaughnessy	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mansoor Mirza	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joseph Vazzano	Independent Director	1.3yrs	US$29.17k	geen gegevens
Laura Benjamin	Independent Director	1.3yrs	US$27.71k	geen gegevens
Ursula Matulonis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roberto Pili	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALLR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Allarity Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Allarity Therapeutics, Inc. Announces Management Appointments

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Board Changes

Recent updates

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics, Inc. Announces Management Appointments

Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics appoints interim CEO, CFO

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd